Hematopoietic Stem Cell Transplantations (HSCT) and Implications in Critically Ill

Each year, more hematopoietic stem cell transplantations are performed. Many patients may get this therapy in the intriguing and rapidly expanding subject of hematology that could save their lives. Patients frequently present with advanced-stage hematologic malignancies treated with multiple cycles of toxic chemotherapy, hampering their immunity and dwindling physiological reserve. Intensivists must comprehend the basic ideas behind bone marrow transplantation and all possible pathophysiology among such patients. There are two types of transplants: donor-derived allogeneic transplants and autologous transplants, in which patients get their own stem cells in conditions such as lymphoma and myeloma. Allogeneic transplants are the only ones associated with graft-versus-host disease. Allograft recipients also need immunosuppression to prevent transplant rejection. Sustaining therapeutic immunosuppression when patients are admitted to the intensive care unit is essential. All transplant recipients have severe immunosuppression and are susceptible to long-lasting neutropenic episodes. They must continue receiving prophylactic antiviral, antifungal, and antibacterial pharmacotherapy upon intensive care shifting. Patients are predisposed to opportunistic infections and iatrogenic complications that present themselves unexpectedly. Adopting a heightened index of suspicion for infectious etiologies and a precise local approach to guide empirical antibiotic therapy is critical. Despite a historically poor prognosis, the future is progressively improving with a multidisciplinary approach for these patients.